The Effect of Ixazomib on the Latent HIV Reservoir

Pilot Study of Ixazomib to Reduce the Number of HIV DNA Positive Lymphoid Cells

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02946047

Enrollment

Registered

2016-10-26

Start date

2017-03-20

Completion date

2019-08-19

Last updated

2022-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human Immunodeficiency Virus (HIV)

Keywords

Antiretroviral Therapy (ART)

Brief summary

The primary purpose of the trial is to determine the safety and tolerability of ixazomib in HIV infected patients on antiretroviral therapy. The secondary purpose is to determine the effect of ixazomib on the size of the HIV reservoir.

Interventions

DRUGIxazomib 1 MG

1 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 1 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.

DRUGIxazomib 2 MG

2mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 2 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.

DRUGIxazomib 3 MG

3 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 3 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.

DRUGIxazomib 4 MG

4 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 4 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.

Study design

Allocation

NON_RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* The following laboratory values obtained \<=14 days prior to registration. * ANC ≥ LLN (lower limit of normal) and ≤ULN (upper limit of normal), Hgb ≥ LLN and ≤ULN, PLT ≥ LLN and ≤ULN * Total bilirubin ≤ULN and the direct bilirubin must be ≤ ULN; AST \<1.5 x ULN and ALT \<1.5 x ULN * Creatinine \<2.0 x ULN and an estimated creatinine clearance \> 60 ml/min * HIV infection with suppressed viral replication on at least 3 active drug ART for at least 6 months * Suppressed viral replication is defined by plasma HIV viral load \<20copies/mL. * Patient must have HIV viral load \<20 copies/ml on two occasions at least 3 months apart. * In the opinion of the treating physician, patients must have available other regimens likely to suppress HIV should their current regimen fail. * Male or female patients age \>=18 years * A plasma HIV RNA viral load demonstrating a measure of \<20 copies/mL within 30 days prior to study initiation. * CD4 count \>500 cells/mm3 within 30 days prior to study enrollment * Females must have a negative pregnancy test prior to receiving the 1st dose of ixazomib and be postmenopausal for at least 1 year before the screen visit, or surgically sterile, * Male patients, even if surgically sterilized (ie, status post-vasectomy), must agree to one of the following: * Agree to practice effective barrier contraception AND a second method of contraception for female partners of childbearing potential during the entire study treatment period and through 90 days after the last dose of ixazomib, * OR * Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods\] and withdrawal are not acceptable methods of contraception.) * AND * Agree to forego sperm donation for the same period as above.

Exclusion criteria

* The following laboratory values obtained \<=14 days prior to registration. * ANC \< LLN and \>ULN, Hgb \< LLN and \>ULN, PLT \< LLN and \>ULN * Total bilirubin \>ULN or the direct bilirubin is \> ULN; AST \>1.5 x ULN or AST \>1.5 x ULN * Creatinine \>=2.0 x ULN or an estimated creatinine clearance \<=60mL/min * Diagnosed and treated for a malignancy within 5 years before randomization, or previously diagnosed with a malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection * Any infection except HIV (excluding benign conditions that is unlikely to be affected or modulated by treatment with ixazomib, e.g. stye or furuncle), or treatment with anti-infective agents within 14 days of enrollment. * Pregnant women * Women of childbearing potential and Nursing women * Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse, while taking the drug and for 90 days after stopping ixazomib. * Any history of peripheral neuropathy, or peripheral neuropathy detected during the screening period. * Major surgery within 14 days before study registration * Systemic treatment with strong CYP3A inducers (rifampin, rifapentine, rifabutin,carbamazepine, phenytoin, phenobarbital), or use of St. John's wort. * Evidence of current uncontrolled cardiovascular conditions, including serious cardiac arrhythmias, congestive heart failure, angina, or myocardial infarction within the past 6 months. * QTc \> 450 milliseconds (msec) for men and \>470 milliseconds for women (83) on a 12 lead ECG obtained during the Screening period. * Known hepatitis B DNA positive status and/or HBsAg positive and/or HBeAg positive, or active hepatitis C replication (HCV RNA positive) or currently on hepatitis C treatment. * Known history of cirrhosis or active liver inflammation, including fatty liver or non-alcohol steatohepatitis (NASH). * Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol. * Known allergy to any of the study medications, their analogues or excipients in the various formulations. * Any other recent or concurrent medical condition that, in the Investigator's opinion, would impose any risk to the patient * Known GI disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing. * Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial.

Design outcomes

Primary

Measure	Time frame	Description
Incidence of Treatment-Emergent Adverse Events	7 months	Number of treatment-emergent adverse events experienced by subjects as defined by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

Secondary

Measure	Time frame	Description
Cell Associated HIV DNA in CD4 T Cell Subsets	24 weeks	HIV copies per million CD4 T cells
Culturable HIV by Quantitative Viral Outgrowth Assay	24 weeks	Infectious units per million CD4 T cells
Absolute CD4 T Cell Count	24 weeks	Cells per microliter
Absolute CD8 T Cell Count	24 weeks	Cells per microliter
CD4/CD8 Ratio	24 weeks	CD4/CD8 T cell count ratio

Countries

United States

Participant flow

Participants by arm

Arm	Count
Ixazomib 1 mg Cohort A: Patients will receive ixazomib 1mg 3 times monthly for 12 weeks, then weekly for 12 weeks. Ixazomib 1 MG: 1 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 1 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.	4
Ixazomib 2 mg Cohort B: Patients will receive ixazomib 2mg 3 times monthly for 12 weeks, then weekly for 12 weeks. Ixazomib 2 MG: 2mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 2 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.	3
Ixazomib 3 mg Cohort C: Patients will receive ixazomib 3 mg 3 times monthly for 12 weeks, then weekly for 12 weeks. Ixazomib 3 MG: 3 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 3 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.	3
Ixazomib 4 mg Cohort D: Patients will receive ixazomib 4mg 3 times monthly for 12 weeks, then weekly for 12 weeks. Ixazomib 4 MG: 4 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 4 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.	7
Total	17

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003
Overall Study	Adverse Event	1	0	0	0

Baseline characteristics

Characteristic	Ixazomib 1 mg	Ixazomib 2 mg	Ixazomib 3 mg	Ixazomib 4 mg	Total
Age, Continuous	54.1 years	49.3 years	51.0 years	49.0 years	51.0 years
Race and Ethnicity Not Collected	—	—	—	—	0 Participants
Region of Enrollment United States	4 participants	3 participants	3 participants	3 participants	7 participants
Sex: Female, Male Female	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants
Sex: Female, Male Male	4 Participants	3 Participants	3 Participants	6 Participants	16 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk
deaths Total, all-cause mortality	0 / 4	0 / 3	0 / 3	0 / 7
other Total, other adverse events	3 / 4	2 / 3	1 / 3	1 / 7
serious Total, serious adverse events	0 / 4	0 / 3	0 / 3	0 / 7

Outcome results

Primary

Incidence of Treatment-Emergent Adverse Events

Number of treatment-emergent adverse events experienced by subjects as defined by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

Time frame: 7 months

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Ixazomib 1 mg	Incidence of Treatment-Emergent Adverse Events	0 Participants
Ixazomib 2 mg	Incidence of Treatment-Emergent Adverse Events	0 Participants
Ixazomib 3 mg	Incidence of Treatment-Emergent Adverse Events	0 Participants
Ixazomib 4 mg	Incidence of Treatment-Emergent Adverse Events	0 Participants

Secondary